BridgeBio Pharma (FRA:2CL) Dividends Received


FRA:2CL BridgeBio Pharma Inc FRA:2CL
71 GF Score
Price €66.20
GF Value €124.98
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:2CL
71GF Score
BridgeBio Pharma Inc FRA:2CL
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €66.20 is trading 47% below its estimated GF Value™ of €124.98. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Dividends Received:
  • GF Value™: €124.98 vs. price of €66.20 (47% below fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
71GF Score

Get the complete analysis for FRA:2CL

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.20
Price
€124.98
GF Value